You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC

Are We Ready for More BTK Inhibitors in Chronic Lymphocytic Leukemia? Experts Discuss the Latest Data

  • Authors: Stephan Stilgenbauer, MD; Anthony Mato, MD; Jennifer A. Woyach, MD; Pier Luigi Zinzani, MD, PhD
  • CME / ABIM MOC Released: 8/24/2022
  • Valid for credit through: 8/24/2023
Start Activity

  • Credits Available

    Physicians - maximum of 0.50 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 0.50 ABIM MOC points

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for hematologists/oncologists who manage patients with CLL.

The goal of this activity is that learners will be able to apply expert feedback on the latest data on BTK inhibitors for relapsed/refractory (R/R) CLL and their implications for the evolving treatment paradigm.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Challenges with managing patients with CLL who are R/R to BTK inhibitors
    • Differences between covalent and noncovalent BTK inhibitors
    • Key new data on BTK inhibitors in R/R CLL
  • Demonstrate greater confidence in their ability to
    • Identify patients with R/R CLL who could benefit from treatment with noncovalent BTK inhibitors


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


Faculty

  • Stephan Stilgenbauer, MD

    Professor of Medicine
    Medical Director, Comprehensive Cancer Center Ulm
    Head, Early Clinical Trials Unit
    Head, Division of CLL
    Department of Internal Medicine III
    Ulm University
    Ulm, Germany

    Disclosures

    Stephan Stilgenbauer, MD, has the following relevant financial relationships:
    Consultant or advisor for: AbbVie; Acerta; Amgen; AstraZeneca; BeiGene; Bristol Myers Squibb Company; Celgene; Genentech; Gilead; GlaxoSmithKline; Hoffmann-La Roche; Incyte; Infinity; Janssen; Novartis; Pharmacyclics; Sunesis; Verastem
    Speaker or member of speakers bureau for: AbbVie; Acerta; Amgen; AstraZeneca; BeiGene; Bristol Myers Squibb Company; Celgene; Genentech; Gilead; GlaxoSmithKline; Hoffmann-La Roche; Incyte; Infinity; Janssen; Novartis; Pharmacyclics; Sunesis; Verastem
    Research funding from: AbbVie; Acerta; Amgen; AstraZeneca; BeiGene; Bristol Myers Squibb Company; Celgene; Genentech; Gilead; GlaxoSmithKline; Hoffmann-La Roche; Incyte; Infinity; Janssen; Novartis; Pharmacyclics; Sunesis; Verastem
    Contracted researcher for: AbbVie; Acerta; Amgen; AstraZeneca; BeiGene; Bristol Myers Squibb Company; Celgene; Genentech; Gilead; GlaxoSmithKline; Hoffmann-La Roche; Incyte; Infinity; Janssen; Novartis; Pharmacyclics; Sunesis; Verastem

  • Anthony Mato, MD

    Associate Professor
    Director, CLL Program
    Memorial Sloan Kettering Cancer Center
    New York, New York, United States

    Disclosures

    Anthony Mato, MD, has no relevant financial relationships.

  • Jennifer A. Woyach, MD

    Professor of Medicine
    Division of Hematology
    The Ohio State University
    Comprehensive Cancer Center
    Columbus, Ohio, United States

    Disclosures

    Jennifer A. Woyach, MD, has the following relevant financial relationships:
    Consultant or advisor for: AbbVie; AstraZeneca; BeiGene; Genentech; LOXO; Newave; Pharmacyclics
    Research funding from: Janssen; Karyopharm; MorphoSys; Pharmacyclics
    Contracted researcher for: Schrödinger

  • Pier Luigi Zinzani, MD, PhD

    Professor
    Head, Lymphoma Group
    Lymphoma and Chronic Lymphoproliferative Syndromes Unit
    Institute of Hematology "L. e A. Serà gnoli"
    University of Bologna
    Bologna, Italy

    Disclosures

    Pier Luigi Zinzani, MD, PhD, has the following relevant financial relationships:
    Consultant or advisor for: AstraZeneca; BeiGene; Bristol Myers Squibb Company; EUSA Pharma; Gilead; Incyte; Janssen; Kyowa Kirin; Merck; Novartis; Roche; Sanofi; Secura Bio; Servier; Takeda
    Speaker or member of speakers bureau for: AstraZeneca; BeiGene; Bristol Myers Squibb Company; EUSA Pharma; Gilead; Incyte; Janssen; Kyowa Kirin; Merck; Novartis; Roche; Sanofi; Servier; Takeda

Editor

  • Sanneke Koekkoek

    Medical Education Director, WebMD Global, LLC

    Disclosures

    Sanneke Koekkoek has no relevant financial relationships.

  • Eloise Ballard, PhD

    Scientific Content Manager, WebMD Global, LLC

    Disclosures

    Eloise Ballard, PhD, has no relevant financial relationships.

Compliance Reviewer

  • Leigh Schmidt, MSN, RN, CNE, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC

Are We Ready for More BTK Inhibitors in Chronic Lymphocytic Leukemia? Experts Discuss the Latest Data

Authors: Stephan Stilgenbauer, MD; Anthony Mato, MD; Jennifer A. Woyach, MD; Pier Luigi Zinzani, MD, PhDFaculty and Disclosures

CME / ABIM MOC Released: 8/24/2022

Valid for credit through: 8/24/2023

processing....

Educational Impact Challenge

The goal of this activity is that learners will be able to apply expert feedback on the latest data on BTK inhibitors for relapsed/refractory (R/R) CLL and their implications for the evolving treatment paradigm.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

  • Print